TrialReader


Effectivity of Dermatix in Promoting Scar Maturation

NCT00548210 — Unknown, 25 participants, Association of Dutch Burn Centres

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Dermatix; A Randomized Controlled Trial Measuring Effectivity of Dermatix in Promoting Scar Maturation of Hypertrophic Scars.

RegistryNCT00548210
StatusUnknown
Study typeObservational
Enrollment25 (Estimated)
SponsorAssociation of Dutch Burn Centres (Other); collaborators: Bausch Health Americas, Inc.
ConditionsHypertrophic Scars
Datesfirst posted 2007-10-23, last updated 2007-10-23
Locations1 site in Netherlands

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Hypertrophic Scars

-Summary

The purpose of this research is to demonstrate effectivity of Dermatix in promoting maturation of the scar, versus a control region that will be treated with an indifferent cream.

Expand all sections  ·  Collapse all

+Detailed description

The healing of deep thermal injuries is always associated with scarring. The healing process can lead to the formation of large scar bundles (e.g. hypertrophic scars). The scars can be discomforting, disfiguring and restrict motion if situated over or near joints. Evidence for effectivity of treatment for reduction of hypertrophic scars or the prevention of them is limited.

Different treatments are used such as intralesional injected steroids, topically used oily creams, silicone sheets or occlusive dressings. Compression garments are also frequently used. There is some evidence as to the effectivity of silicone sheets for recuction of hypertrophic scarring, however, these sheets cannot be used easily on all anatomical locations.

Valeant Pharmaceuticals International has developed a silicone based scar remodelling gel, Dermatix®, which has been empirically shown by others to have potential to reduce hypertrophic scars.

Primary objectives are to demonstrate effectivity of Dermatix in promoting maturation of the scar, versus a control region that will be treated with an indifferent cream.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

1. Patients with hypertrophic scarring and/or ropes, stable for at least 3 months before inclusion.
2. Written informed consent
3. Scar size enabling the definition of two distinct scar areas, with similar scar characteristics at inclusion, preferably symmetric scars.
4. Patients of 18 years or older

Exclusion criteria:

1. Known sensitivity for occlusive dressings or silicone containing products
2. Any patient condition that may influence the compliance of the treatment negatively.

+Locations (1)

FacilityCityCountryStatus
Association of Dutch Burn CentresBeverwijk, North HollandNetherlandsRecruiting

+Investigators

My Notes